A detailed history of Natixis Advisors, L.P. transactions in Genmab A/S stock. As of the latest transaction made, Natixis Advisors, L.P. holds 206,563 shares of GMAB stock, worth $4.2 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
206,563
Previous 159,126 29.81%
Holding current value
$4.2 Million
Previous $4 Million 25.93%
% of portfolio
0.01%
Previous 0.01%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$23.84 - $28.48 $1.13 Million - $1.35 Million
47,437 Added 29.81%
206,563 $5.04 Million
Q2 2024

Aug 01, 2024

SELL
$25.13 - $30.27 $1.93 Million - $2.33 Million
-76,848 Reduced 32.57%
159,126 $4 Million
Q1 2024

Apr 25, 2024

BUY
$26.43 - $32.77 $1.27 Million - $1.58 Million
48,176 Added 25.65%
235,974 $7.06 Million
Q4 2023

Feb 06, 2024

SELL
$27.94 - $35.44 $1.15 Million - $1.46 Million
-41,099 Reduced 17.96%
187,798 $5.98 Million
Q3 2023

Nov 13, 2023

BUY
$35.27 - $42.24 $2.26 Million - $2.71 Million
64,085 Added 38.88%
228,897 $8.07 Million
Q2 2023

Aug 15, 2023

SELL
$37.4 - $42.94 $470,679 - $540,399
-12,585 Reduced 7.09%
164,812 $6.27 Million
Q1 2023

May 11, 2023

SELL
$34.88 - $43.22 $799,100 - $990,170
-22,910 Reduced 11.44%
177,397 $6.7 Million
Q4 2022

Jan 27, 2023

SELL
$33.8 - $47.06 $1.25 Million - $1.74 Million
-36,907 Reduced 15.56%
200,307 $8.49 Million
Q3 2022

Nov 14, 2022

BUY
$31.52 - $373.61 $3.44 Million - $40.8 Million
109,103 Added 85.16%
237,214 $7.62 Million
Q2 2022

Aug 12, 2022

SELL
$26.83 - $38.57 $680,703 - $978,559
-25,371 Reduced 16.53%
128,111 $4.16 Million
Q1 2022

May 12, 2022

BUY
$30.95 - $39.68 $272,669 - $349,580
8,810 Added 6.09%
153,482 $5.55 Million
Q4 2021

Feb 08, 2022

SELL
$35.87 - $47.12 $2,331 - $3,062
-65 Reduced 0.04%
144,672 $5.72 Million
Q3 2021

Nov 15, 2021

SELL
$41.55 - $48.72 $630,355 - $739,131
-15,171 Reduced 9.49%
144,737 $6.33 Million
Q2 2021

Aug 12, 2021

BUY
$32.88 - $44.57 $1.12 Million - $1.52 Million
34,095 Added 27.1%
159,908 $6.53 Million
Q1 2021

May 05, 2021

SELL
$30.92 - $44.4 $274,878 - $394,716
-8,890 Reduced 6.6%
125,813 $4.13 Million
Q4 2020

Feb 12, 2021

BUY
$33.66 - $40.76 $70,686 - $85,596
2,100 Added 1.58%
134,703 $5.48 Million
Q3 2020

Nov 12, 2020

SELL
$33.07 - $38.68 $862,267 - $1.01 Million
-26,074 Reduced 16.43%
132,603 $4.86 Million
Q2 2020

Aug 11, 2020

SELL
$20.05 - $33.89 $3.6 Million - $6.09 Million
-179,779 Reduced 53.12%
158,677 $5.38 Million
Q1 2020

Apr 27, 2020

BUY
$17.15 - $25.22 $912,808 - $1.34 Million
53,225 Added 18.66%
338,456 $7.17 Million
Q4 2019

Feb 10, 2020

BUY
$18.88 - $24.14 $118,944 - $152,082
6,300 Added 2.26%
285,231 $6.37 Million
Q3 2019

Nov 12, 2019

BUY
$18.0 - $21.38 $5.02 Million - $5.96 Million
278,931 New
278,931 $5.65 Million

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $13.4B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Natixis Advisors, L.P. Portfolio

Follow Natixis Advisors, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Natixis Advisors, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Natixis Advisors, L.P. with notifications on news.